2-Methyl-2-aza-adamantan | 3314-24-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-Methyl-2-aza-adamantan
• 英文别名: 2-Methyl-2-azatricyclo[3.3.1.1~3,7~]decane；2-methyl-2-azatricyclo[3.3.1.13,7]decane
• CAS: 3314-24-7
• 化学式: C₁₀H₁₇N
• 分子量: 151.252
• InChiKey: JDQFZGRYSUMQTF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (3R,4S,7R,8S)-2-methyl-2-azatricyclo[3.3.1.13,7]decane-4,8-diol 在 lithium aluminium tetrahydride 、 氯化亚砜 作用下， 生成 2-Methyl-2-aza-adamantan
  参考文献：
  名称：

  底物定向的取代2-氮杂金刚烷的合成

  摘要：

  已经开发了控制取代基立体化学的单取代和二取代的2-氮杂金刚烷的合成。

  DOI：

  10.1016/s0040-4039(00)88995-9

文献信息

• HEPATITIS B ANTIVIRAL AGENTS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20170217974A1

  公开（公告）日：2017-08-03

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-Z-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了化合物的结构式（I）或其药学上可接受的盐、酯或前药： X-A-Y-Z-R  (I) 这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的生命周期功能，并且还可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• OXIDATION REACTION EXCELLENT IN CONVERSION RATE
  申请人：PAION UK LIMITED

  公开号：US20160009680A1

  公开（公告）日：2016-01-14

  A process for preparing 3-[(S)-7-bromo-2-(2-oxo-propylamino)-5-pyridin-2-yl-3H-1,4,-benzodiazepin-3-yl]propionic acid methyl ester at a high conversion rate with good reproducibility by oxidizing 3-[(S)-7-bromo-2-(2-hydroxy-propylamino)-5-pyridin-2-yl-3H-benzo[e][1,4]diazepin-3-yl]propionic acid methyl ester in the presence of an oxidation catalyst is provided by defining the ammonium ion content of 3-[(S)-7-bromo-2-(2-hydroxy-propylamino)-5-pyridin-2-yl-3H-benzo[e][1,4]diazepin-3-yl]propionic acid methyl ester.

  提供一种通过在氧化催化剂存在下氧化3-[(S)-7-溴-2-(2-羟基丙基氨基)-5-吡啶-2-基-3H-苯并二氮杂环-3-基]丙酸甲酯，以高转化率和良好的可重复性制备3-[(S)-7-溴-2-(2-氧代丙基氨基)-5-吡啶-2-基-3H-1,4-苯并二氮杂环-3-基]丙酸甲酯的方法，通过确定3-[(S)-7-溴-2-(2-羟基丙基氨基)-5-吡啶-2-基-3H-苯并二氮杂环-3-基]丙酸甲酯中铵离子含量实现。
• CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE AND METHODS FOR MAKING AND USING THEM
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20150361060A1

  公开（公告）日：2015-12-17

  In alternative embodiments, the invention provides nucleophilic hydroxyimino-acetamido alkylamine antidotes that cross the blood-brain barrier (BBB) to catalyze the hydrolysis of organophosphate (OP)-inhibited human acetylcholinesterase (hAChE) in the central nerve system (CNS). The hydroxyimino-acetamido alkylamines of the invention are designed to fit within AChE active center gorge dimensions, bind with reasonable affinity, and react with the conjugated phosphate atom in the gorge. The hydroxyimino-acetamido alkylamines of the invention are also designed to possess ionization states that govern affinity and reactivity for the two linked hAChE re-activation steps. In alternative embodiments, the invention provides pumps, devices, subcutaneous infusion devices, continuous subcutaneous infusion devices, infusion pens, needles, reservoirs, ampoules, a vial, a syringe, a cartridge, a disposable pen or jet injector, a prefilled pen or a syringe or a cartridge, a cartridge or a disposable pen or jet injector, a two chambered or multi-chambered pump, a syringe, a cartridge or a pen or a jet injector, comprising a compound of the invention.

  在另一种实施方式中，本发明提供了能够穿过血脑屏障（BBB）的亲核羟肟酰胺基烷基胺解毒剂，以催化中枢神经系统（CNS）中有机磷（OP）抑制的人类乙酰胆碱酯酶（hAChE）的水解。本发明的羟肟酰胺基烷基胺被设计为适合于AChE活性中心峡谷尺寸，具有合理的亲和力，并与峡谷中的共轭磷原子发生反应。本发明的羟肟酰胺基烷基胺也被设计为具有离子化状态，以控制与两个链接的hAChE再活化步骤的亲和力和反应性。在另一种实施方式中，本发明提供了泵、装置、皮下输注装置、连续皮下输注装置、输注笔、针头、储液器、安瓿、小瓶、注射器、芯片、一次性笔或喷射器、预装笔或注射器或芯片、芯片或一次性笔或喷射器、两室或多室泵、注射器、芯片或笔或喷射器，包括本发明的化合物。
• Centrally active and orally bioavailable antidotes for organophosphate exposure and methods for making and using them
  申请人：The Regents of the University of California

  公开号：US10913726B2

  公开（公告）日：2021-02-09

  In alternative embodiments, the invention provides nucleophilic hydroxyimino-acetamido alkylamine antidotes that cross the blood-brain barrier (BBB) to catalyze the hydrolysis of organophosphate (OP)-inhibited human acetylcholinesterase (hAChE) in the central nerve system (CNS). The hydroxyimino-acetamido alkylamines of the invention are designed to fit within AChE active center gorge dimensions, bind with reasonable affinity, and react with the conjugated phosphate atom in the gorge. The hydroxyimino-acetamido alkylamines of the invention are also designed to possess ionization states that govern affinity and reactivity for the two linked hAChE re-activation steps. In alternative embodiments, the invention provides pumps, devices, subcutaneous infusion devices, continuous subcutaneous infusion devices, infusion pens, needles, reservoirs, ampoules, a vial, a syringe, a cartridge, a disposable pen or jet injector, a prefilled pen or a syringe or a cartridge, a cartridge or a disposable pen or jet injector, a two chambered or multi-chambered pump, a syringe, a cartridge or a pen or a jet injector, comprising a compound of the invention.

  在另一个实施方案中，本发明提供了亲核羟基亚氨基乙酰氨基烷基胺解毒剂，它可以穿过血脑屏障（BBB），催化中枢神经系统（CNS）中被有机磷（OP）抑制的人乙酰胆碱酯酶（hAChE）的水解。本发明的羟基亚氨基乙酰胺基烷基胺设计成适合 AChE 活性中心峡部尺寸，以合理的亲和力结合，并与峡部的共轭磷酸原子反应。本发明的羟基亚氨基乙酰氨基烷基胺还被设计成具有电离状态，这种电离状态可控制两个相连的 hAChE 再激活步骤的亲和性和反应性。在其他实施方案中，本发明提供了包含本发明化合物的泵、装置、皮下输液装置、连续皮下输液装置、输液笔、针头、贮液器、安瓿瓶、小瓶、注射器、针筒、一次性笔或喷射注射器、预填充笔或注射器或针筒、针筒或一次性笔或喷射注射器、双腔或多腔泵、注射器、针筒或笔或喷射注射器。
• NEW 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION
  申请人：Phadke Avinash

  公开号：US20140113890A1

  公开（公告）日：2014-04-24

  The invention provides 4-amino-4-oxobutanoyl peptides of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R 1 , R 6 -R 8 , R 16 , R 18 , R 19 , M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. The 4-amino-4-oxobutanoyl peptides disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptides and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a 4-amino-4-oxobutanoyl peptides as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptides and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections.

表征谱图